PeptiDream has initiated a Phase 1 clinical trial for the type 1 TNF receptor inhibitor ‘AK1940’, co-developed with Asahi Kasei Therapeutics. The company holds the right to receive milestone fees, with no changes to earnings guidance.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4587","jir_company_name":"PeptiDream Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-04-20","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/4587-20260420-01.pdf","jir_short_summary":"PeptiDream has initiated a Phase 1 clinical trial for the type 1 TNF receptor inhibitor 'AK1940', co-developed with Asahi Kasei Therapeutics. The company holds the right to receive milestone fees, with no changes to earnings guidance.","jir_summary":"### Overview of Phase 1 Clinical Trial Initiation\nPeptiDream Inc. announced the initiation of a Phase 1 clinical trial for 'AK1940', a type 1 TNF receptor inhibitor co-developed with Asahi Kasei Therapeutics. This compound is a cyclic peptide created using PeptiDream's proprietary drug discovery platform PDPS and is expected to contribute broadly as a treatment for autoimmune diseases.\n\n### Outlook and Impact on Earnings\nWith the start of the Phase 1 clinical trial, PeptiDream holds the right to receive milestone fees, although the amount is undisclosed. There is no change to the earnings guidance for the fiscal year ending December 2026, and milestone fees and royalties are expected to be received according to future clinical progress.","jir_financial_highlights":"Milestone Fees: Amount undisclosed (New right to receive acquired)\nEarnings Guidance: Unknown (No change)","jir_category":"","jir_hashtags":"#PeptiDream, #NewDrugDevelopment, #ClinicalTrialInitiation","jir_key_figures":"Phase 1 Clinical Trial Start Date: 2026-04-20\nMilestone Fees: Amount undisclosed\nEarnings Guidance: No change for the fiscal year ending December 2026","jir_meta_title":"[PeptiDream] Phase 1 Clinical Trial Initiation for Type 1 TNF Receptor Inhibitor | April 2026","jir_meta_description":"PeptiDream has started a Phase 1 clinical trial for 'AK1940', a type 1 TNF receptor inhibitor co-developed with Asahi Kasei Therapeutics. Holds milestone fee receipt rights with no changes to earnings guidance.","jir_og_title":"[PeptiDream] Phase 1 Clinical Trial Initiation for Type 1 TNF Receptor Inhibitor | April 2026","jir_og_description":"PeptiDream has initiated the Phase 1 clinical trial of the co-developed new drug 'AK1940'. The company holds rights to milestone fees and maintains its earnings guidance.","jir_og_image_url":"\/assets\/og\/company-product_announcement.jpg","jir_chart_data_collection":"[]","ir_related_company":8926,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"product_announcement","footnotes":""},"sector":[],"importance":[],"class_list":["post-41393","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n